Fundraising FoxOncternal Therapeutics
Del Mar, US · Founded 2013 · Delaware corporation · 2 known investors
Find your way into Oncternal Therapeutics
Sign up to find every way you can get introduced to Oncternal Therapeutics
- Your email: who you already know at Oncternal Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Oncternal Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Clinical-stage oncology company developing cancer treatments
Founders & leadership
DM
Dana McGowanTreasurer and Secretary
KL
Karen LundgrenVice President and Chief Scientific Officer
JF
James FreddoChief Medical Officer
JB
James B. Breitmeyer, M.D., Ph.D.President and Chief Executive Officer
Board
Investors · 2
Reported raises · per SEC filings
Form D private placements$58.1M disclosed across 6 rounds · 2014–2018
▶$17MraisedNov 2018 · 1 investors · BiotechnologyRule 506(b)
▶$17MraisedNov 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard VincentExecutive Officer
- Cam GallagherDirector
- Scott L. GlennDirector
- James B. Breitmeyer, M.D., Ph.D.Executive Officer, Director
- Cooper CollinsDirector
- David F. HaleDirector
- Charles Theuer, M.D.Director
- Lauren G. OtsukiExecutive Officer
- William R. LaRueDirector
- Offering amount
- $24M
- Amount sold
- $17M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$6.9MraisedSep 2017 · 121 investors · BiotechnologyRule 506(b)
▶$6.9MraisedSep 2017 · 121 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David JohnsonDirector
- James B. Breitmeyer, M.D., Ph.D.Executive Officer, Director
- Scott L. GlennDirector
- Richard VincentExecutive Officer
- Lauren G. OtsukiExecutive Officer
- Cooper CollinsDirector
- Brian LannuttiExecutive Officer
- Cam GarnerDirector
- Cam GallagherDirector
- David F. HaleDirector
- Langdon MillerExecutive Officer
- Offering amount
- $11.3M
- Amount sold
- $6.9M
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$17.9MraisedMar 2017 · 111 investors · BiotechnologyRule 506(b)
▶$17.9MraisedMar 2017 · 111 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott L. GlennDirector
- Brian LannuttiExecutive Officer
- Cam GarnerDirector
- Cam GallagherDirector
- David F. HaleDirector
- Langdon MillerExecutive Officer
- Lauren G. OtsukiExecutive Officer
- David JohnsonDirector
- James B. Breitmeyer, M.D., Ph.D.Executive Officer, Director
- Offering amount
- $23.5M
- Amount sold
- $17.9M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$150KraisedJul 2016 · 3 investors · BiotechnologyRule 506(b)
▶$150KraisedJul 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lauren G. OtsukiExecutive Officer
- David F. HaleDirector
- James B. Breitmeyer, M.D., Ph.D.Director, Executive Officer
- David JohnsonDirector
- James FreddoExecutive Officer
- Brian LannuttiExecutive Officer
- Dana McGowanExecutive Officer
- Scott GlennDirector
- Cam GarnerDirector
- Offering amount
- $3.3M
- Amount sold
- $150K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$13.1MraisedJun 2016 · 26 investors · BiotechnologyRule 506(b)
▶$13.1MraisedJun 2016 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dana McGowanExecutive Officer
- Karen LundgrenExecutive Officer
- Lauren G. OtsukiExecutive Officer
- James FreddoExecutive Officer
- David F. HaleDirector
- Scott GlennDirector
- Cam GarnerDirector
- James B. Breitmeyer, M.D., Ph.D.Director, Executive Officer
- David JohnsonDirector
- Offering amount
- $13.1M
- Amount sold
- $13.1M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$3.1MraisedMar 2014 · 26 investors · BiotechnologyRule 506(b)
▶$3.1MraisedMar 2014 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David F. HaleDirector
- Cam GarnerDirector
- Scott L. GlennExecutive Officer, Director
- Offering amount
- $3.3M
- Amount sold
- $3.1M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Oncternal Therapeutics went on to found or lead other companies.
Related companies · 6
Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Sionna TherapeuticsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
RadioneticsRadionetics develops small molecule radiopharmaceuticals targeting GPCRs for cancer therapy and diagnosis, using a precision medicine approach that combines radioisotopes with potent, selective ligands. The company is headquartered in San Diego, California, and focuses on theranostic applications in oncology.
Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Companies working in the same space as Oncternal Therapeutics.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $753.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $297.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2003 | $140.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2003 | $130.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Oncternal Therapeutics do?
- Clinical-stage oncology company developing cancer treatments
- Who are Oncternal Therapeutics's investors?
- Oncternal Therapeutics's investors include MESA VERDE VENTURE PARTNERS, Vedanta Capital.
- How much funding has Oncternal Therapeutics raised?
- Oncternal Therapeutics has disclosed $58.1M raised across 6 rounds.
- Where is Oncternal Therapeutics headquartered?
- Oncternal Therapeutics is headquartered in Del Mar, US.